MA29984B1 - Antagonistes du recepteur de crf et procedes correspondants - Google Patents

Antagonistes du recepteur de crf et procedes correspondants

Info

Publication number
MA29984B1
MA29984B1 MA29147A MA29147A MA29984B1 MA 29984 B1 MA29984 B1 MA 29984B1 MA 29147 A MA29147 A MA 29147A MA 29147 A MA29147 A MA 29147A MA 29984 B1 MA29984 B1 MA 29984B1
Authority
MA
Morocco
Prior art keywords
crf receptor
receptor antagonists
methods
crf
pharmaceutically acceptable
Prior art date
Application number
MA29147A
Other languages
English (en)
Inventor
Zhiyong Luo
Deborah Slee
John Edward Tellew
John Williams
Xiaohu Zhang
Original Assignee
Neurocrine Biosciences Inc
Sb Pharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc, Sb Pharmco Inc filed Critical Neurocrine Biosciences Inc
Publication of MA29984B1 publication Critical patent/MA29984B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Antagonistes du récepteur de CRF et méthodes les concernant Il est décrit des antagonistes du récepteur de CRF qui sont utiles dans le traitement de diverses affections, comprenant le traitement d'affections se manifestant par une hypersécrétion de CRF chez des animaux à sang chaud, telles qu'un ictus. Les antagonistes du récepteur de CRF de la présente invention ont la structure (I) suivante, et comprennent leurs stéréoisomères, leurs précurseurs médicamenteux et leurs sels pharmaceutiquement acceptables, structure dans laquelle R1, R2, R3, Y, Ar et H et sont tels que définis dans le présent mémoire. Il est décrit également des compositions contenant un antagoniste du récepteur de CRF en association avec un support pharmaceutiquement acceptable, ainsi que des méthodes pour leur utilisation.
MA29147A 2003-12-22 2006-06-27 Antagonistes du recepteur de crf et procedes correspondants MA29984B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53203103P 2003-12-22 2003-12-22

Publications (1)

Publication Number Publication Date
MA29984B1 true MA29984B1 (fr) 2008-12-01

Family

ID=34738733

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29147A MA29984B1 (fr) 2003-12-22 2006-06-27 Antagonistes du recepteur de crf et procedes correspondants

Country Status (19)

Country Link
US (1) US7737154B2 (fr)
EP (1) EP1697374B1 (fr)
JP (1) JP4926720B2 (fr)
KR (1) KR20070009537A (fr)
CN (1) CN1938309B (fr)
AR (1) AR046967A1 (fr)
AU (1) AU2004309168B2 (fr)
BR (1) BRPI0417943A (fr)
CA (1) CA2550948A1 (fr)
IL (1) IL176350A0 (fr)
IS (1) IS8526A (fr)
MA (1) MA29984B1 (fr)
MY (1) MY143499A (fr)
NO (1) NO20063230L (fr)
NZ (1) NZ547990A (fr)
RU (1) RU2394035C2 (fr)
TW (1) TW200530242A (fr)
WO (1) WO2005063755A1 (fr)
ZA (1) ZA200604574B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US7652035B2 (en) * 2004-10-19 2010-01-26 Neurocrine Bioscience, Inc. CRF receptor antagonists and methods relating thereto
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
JP5184536B2 (ja) * 2006-09-20 2013-04-17 イーライ リリー アンド カンパニー チオフェンピラゾロピリミジン化合物
HRP20100516T1 (hr) 2006-09-20 2010-10-31 Eli Lilly And Company Tiazolpirazolopirimidini kao antagonisti receptora crf1
KR100854679B1 (ko) * 2007-02-03 2008-08-27 김기형 심플 서비스 로케이션 프로토콜 네트워크 시스템 및 이를구성하는 에이전트.
EP2282998B1 (fr) * 2008-04-21 2014-09-10 Albemarle Corporation Procédés de production du n-alkylpyrazole
JP5748777B2 (ja) * 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
WO2014060381A1 (fr) 2012-10-18 2014-04-24 Bayer Cropscience Ag Composés hétérocycliques pour la lutte contre les nuisibles
JP2016503395A (ja) 2012-10-31 2016-02-04 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 病害生物防除剤としての複素環化合物
RU2672722C2 (ru) * 2014-04-10 2018-11-19 Хубэй Био-Фармасьютикал Индастриал Текнолоджикал Инститьют Инк. Аналоги соединений 4н-пиразоло[1,5-а]бензимидазола в качестве ингибиторов parp
WO2019036503A1 (fr) 2017-08-14 2019-02-21 Spruce Biosciences, Inc. Antagonistes du récepteur du facteur de libération de la corticotropine
EP4643950A3 (fr) 2018-04-27 2026-01-14 Spruce Biosciences, Inc. Méthodes de traitement de tumeurs de repos surrénales testiculaires et ovariennes
CN116829558A (zh) * 2020-07-27 2023-09-29 艾斯法姆生物技术股份有限公司 化合物
KR20240023691A (ko) 2020-08-12 2024-02-22 스프루스 바이오사이언시스 인코포레이티드 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU713673B2 (en) * 1996-02-07 1999-12-09 Neurocrine Biosciences Inc. Pyrazolopyrimidines as crf receptor antagonists
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
HU229024B1 (en) 1996-07-24 2013-07-29 Bristol Myers Squibb Pharma Co Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
JP3621706B2 (ja) 1996-08-28 2005-02-16 ファイザー・インク 置換された６，５―ヘテロ―二環式誘導体
JP2002501532A (ja) * 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド 新規血管形成阻害薬
ATE301657T1 (de) * 1998-01-28 2005-08-15 Bristol Myers Squibb Pharma Co Azolo-pyrimidine
AU4203500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
ES2277855T3 (es) 1999-09-30 2007-08-01 Neurogen Corporation Pirazolo-(1,5-a)-1,5-pirimidinas y pirazolo-(1,5-a)-1,3,5-triazinas amino sustituidas.
CO5271670A1 (es) 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
DE60225127T2 (de) 2001-04-30 2009-02-19 Glaxo Group Ltd., Greenford Kondensierte pyrimidine als antagonisten des corticotropin releasing factor (crf)
EP1395591B1 (fr) 2001-06-12 2008-06-04 Glaxo Group Limited Antagonistes du facteur de liberation de la corticotropine
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
WO2004062665A1 (fr) 2003-01-16 2004-07-29 Sb Pharmco Puerto Rico Inc Derives pyrrolo[2,3-b]pyridine a substitution heteroaryle utilises comme antagonistes des recepteurs du crf
US20070179161A1 (en) 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US20070021429A1 (en) 2003-04-09 2007-01-25 Yves St-Denis Condensed n-heterocyclic compounds and their use as crf receptor antagonists
JP2007515474A (ja) 2003-12-22 2007-06-14 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法
DE102004008807A1 (de) 2004-02-20 2005-09-08 Bayer Cropscience Ag Pyrazolopyrimidine
US7652035B2 (en) 2004-10-19 2010-01-26 Neurocrine Bioscience, Inc. CRF receptor antagonists and methods relating thereto
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US8088779B2 (en) 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists

Also Published As

Publication number Publication date
TW200530242A (en) 2005-09-16
KR20070009537A (ko) 2007-01-18
MY143499A (en) 2011-05-31
IS8526A (is) 2006-07-11
NO20063230L (no) 2006-09-12
WO2005063755A1 (fr) 2005-07-14
AR046967A1 (es) 2006-01-04
CA2550948A1 (fr) 2005-07-14
ZA200604574B (en) 2007-11-28
NZ547990A (en) 2010-04-30
AU2004309168A1 (en) 2005-07-14
EP1697374A1 (fr) 2006-09-06
US20070287705A1 (en) 2007-12-13
AU2004309168B2 (en) 2009-04-23
CN1938309A (zh) 2007-03-28
BRPI0417943A (pt) 2007-04-17
IL176350A0 (en) 2006-10-05
EP1697374B1 (fr) 2012-08-29
JP2007515472A (ja) 2007-06-14
RU2006126675A (ru) 2008-01-27
CN1938309B (zh) 2011-11-09
RU2394035C2 (ru) 2010-07-10
US7737154B2 (en) 2010-06-15
JP4926720B2 (ja) 2012-05-09

Similar Documents

Publication Publication Date Title
MA29984B1 (fr) Antagonistes du recepteur de crf et procedes correspondants
TNSN05249A1 (fr) Benzopyrannes utiles pour le traitement d'etats inflammatoires
TNSN06358A1 (fr) Methyl-aryl-ou-heteroaryl-amides substitues
MA31763B1 (fr) Inhibiteurs de kinase de type polo
TNSN06359A1 (fr) Aryl-ou heteroaryl-amides substitues en position ortho
TNSN06347A1 (fr) Derives de morpholine
TN2009000471A1 (fr) Composes amino-heterocycliques
MA27142A1 (fr) Derives de piperazine a activite antagoniste des recepteurs ccr1
TNSN05250A1 (fr) Pyrimidinones substituees
TNSN06109A1 (fr) Derives [3.1.0] bicycliques servant d'inhibiteurs du transporteur de glycine
DE60305484D1 (de) Verbindungen und deren verwendung als 5-ht inhibitore
MA29713B1 (fr) Derives de tetrahydroindolone et de tetrahydroindazolone
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA31761B1 (fr) Nouveaux inhibiteurs de seh et leur utilisation
MA29250B1 (fr) Cyclohexylamides servant d'antagonistes des recepteurs de dopamine d3, d2 et de 5ht1a
MA27568A1 (fr) Derives de pyrrolopyrimidine
MA27569A1 (fr) Derives de pyrrolo-pyrazole substitues servant d'inhibiteurs de kinases
AR022019A1 (es) Un compuesto de imidazol y las composiciones farmaceuticas que lo contienen
TN2009000204A1 (fr) Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase
MA27926A1 (fr) Derives de quinoline et de quinazoline presentant une affinite vis-a-vis des recepteurs du type 5ht1
TNSN04156A1 (fr) Pyridinones substituees servant de modulateurs de la map-kinase p38
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA28064A1 (fr) Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA27197A1 (fr) Sels de tolterodine